Literature DB >> 14609682

Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease.

Christophe Jollivet1, Anne Aubert-Pouessel, Anne Clavreul, Marie Claire Venier-Julienne, Séverine Remy, Claudia N Montero-Menei, Jean Pierre Benoit, Philippe Menei.   

Abstract

The recent identification of neurotrophic factors, such as the glial cell line derived neurotrophic factor (GDNF), acting on mesencephalic dopaminergic neurons, offers the possibility to stimulate the axonal regeneration of these cells which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. We have developed GDNF-releasing microspheres capable of releasing the neurotrophic factor for at least 2 months in vivo. In this study we demonstrate that these microspheres, when implanted in the brains of 'Parkinsonian' rats, were well tolerated, and were able to induce sprouting of the preserved dopaminergic fibers with synaptogenesis. Moreover, this neural regeneration was accompanied by functional improvement. The implantation of GDNF-releasing microspheres could be a promising strategy in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14609682     DOI: 10.1016/s0142-9612(03)00601-x

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  15 in total

1.  Availability of Pre- and Pro-regions of Transgenic GDNF Affects the Ability to Induce Axonal Sprout Growth.

Authors:  Nadezda Kust; Dmitri Panteleev; Ilya Mertsalov; Ekaterina Savchenko; Ekaterina Rybalkina; Alexander Revishchin; Galina Pavlova
Journal:  Mol Neurobiol       Date:  2014-07-03       Impact factor: 5.590

2.  Controlled release of glial cell line-derived neurotrophic factor from poly(ε-caprolactone) microspheres.

Authors:  Andrew Agbay; Nima Khadem Mohtaram; Stephanie Michelle Willerth
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

3.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

4.  Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson's disease.

Authors:  Nicolas Daviaud; Elisa Garbayo; Laurence Sindji; Alberto Martínez-Serrano; Paul C Schiller; Claudia N Montero-Menei
Journal:  Stem Cells Transl Med       Date:  2015-04-29       Impact factor: 6.940

5.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

6.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 7.  Methods to assess in vitro drug release from injectable polymeric particulate systems.

Authors:  Susan S D'Souza; Patrick P DeLuca
Journal:  Pharm Res       Date:  2006-01-13       Impact factor: 4.580

Review 8.  Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain.

Authors:  Olesja Bondarenko; Mart Saarma
Journal:  Front Cell Neurosci       Date:  2021-06-02       Impact factor: 5.505

Review 9.  Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria.

Authors:  Wisberty J Gordián-Vélez; Dimple Chouhan; Rodrigo A España; H Isaac Chen; Jason A Burdick; John E Duda; D Kacy Cullen
Journal:  Brain Res Bull       Date:  2021-07-28       Impact factor: 3.715

10.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.